Galectin-3 as a possible marker for increased thrombogenicity in COVID-19

Back

ESC Professional Premium Access

Galectin-3 as a possible marker for increased thrombogenicity in COVID-19

Session: COVID-19 and cardiovascular disease in special populations

Topic: Autoimmune/Chronic Inflammatory Disorders and Heart Disease

Speaker: Mrs M. Puccini (Berlin, DE)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Mrs Marianna Puccini

Charite University Hospital, Berlin (Germany)

0 follower

5 more presentations in this session

COVID-19 vaccine-induced myocarditis vs. Immune checkpoint inhibitor-induced myocarditis - Same but different?

Speaker: Doctor M. Laufer-Perl (Tel Aviv, IL)

Access

Abstract

Slides

Impaired endothelial glycocalyx, vascular dysfunction and myocardial deformation four months after COVID-19 infection are partially improved at twelve months.

Speaker: Doctor I. Ikonomidis (Athens, GR)

Access

Abstract

Slides

Predictors and clinical consequences of heart damage in CMR in patients after COVID-19

Speaker: Doctor M. Chudzik (Warsaw, PL)

Access

Abstract

Slides

Parameters of coagulation and platelet hyperreactivity reflect an increased mortality in patients with moderate to severe COVID-19

Speaker: Mr K. Jakobs (Berlin, DE)

Access

Abstract

Slides

Pragmatic observations from a post-Covid-19 cardiac evaluation register: prevalence of cardiological alterations from a basic diagnostic sequence and contribution of the clinical hystory.

Speaker: Doctor G. Ruiz (Buenos Aires, AR)

Access

Abstract

Slides

Access the full session

COVID-19 and cardiovascular disease in special populations

Speakers: Mrs M. Puccini, Doctor M. Laufer-Perl, Doctor I. Ikonomidis, Doctor M. Chudzik, Mr K. Jakobs...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources